Synendos Therapeutics Expands Series A to CHF 24 million with new investment. Ysios Capital joins other investors

by Ysios Capital

​Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today annou...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio preclínico mejora el tratami...

by CIMA - Centro de Investigación Médica Aplicada

Investigadores del Cima Universidad de Navarra constatan que la combin...

Photos Stream